F. Gibbs and . Zoulim, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, vol.126, pp.1750-1758, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00133134

P. Bedossa and . Marcellin, High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study, J. Hepatol, vol.50, 2009.

C. Marchand, J. Trépo, F. Kao, K. Carrat, R. F. Lacombe et al., Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure, Gut, pp.64-1314, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01263140

W. Sheng, J. Kao, P. Chen, L. Huang, S. Chang et al., Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy, Clinical Infectious Diseases, vol.45, issue.9, pp.45-1221, 2007.
DOI : 10.1086/522173

A. Boyd, J. Gozlan, P. Miailhes, C. Lascoux-combe, M. S. Cam et al., Rates and determinants of hepatitis B ???e??? antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus, AIDS, vol.29, issue.15, pp.1963-1973, 2015.
DOI : 10.1097/QAD.0000000000000795

C. Kroon, A. A. Richter, M. J. Van-der-eijk, B. E. Sonneveld, R. A. Hansen et al., Hepatitis B surface antigen declines and clearance during longterm tenofovir therapy in patients coinfected with HBV and HIV, J. Infect. Dis, vol.206, pp.974-980, 2012.

S. Kinn, S. Akhavan, H. Agut, and V. Thibault, Performance of the DiaSorin LIAISON?? anti-HBs II for the detection of hepatitis B surface antibodies: Comparison with the Abbott Architect anti-HBs assay, Journal of Clinical Virology, vol.50, issue.4, pp.297-302, 2011.
DOI : 10.1016/j.jcv.2011.01.009

J. Boibieux, C. Bottero, F. Trepo, and . Zoulim, Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients, J. Viral Hepat, vol.18, pp.61-69, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00851726

D. Le, J. D. Miller, and V. V. Ganusov, Mathematical modeling provides kinetic details of the human immune response to vaccination, Front, Cell. Infect. Microbiol, vol.4

M. C. Honorati, A. Palareti, P. Dolzani, C. A. Busachi, R. Rizzoli et al., A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B, Clinical and Experimental Immunology, vol.175, issue.1, pp.121-126, 1999.
DOI : 10.1016/0168-8278(89)90013-5

S. M. Ciupe, R. M. Ribeiro, and A. S. Perelson, Antibody Responses during Hepatitis B Viral Infection, PLoS Computational Biology, vol.54, issue.7
DOI : 10.1371/journal.pcbi.1003730.s006
URL : http://doi.org/10.1371/journal.pcbi.1003730

M. H. Zwietering, I. Jongenburger, F. M. Rombouts, and K. , van 't Riet, Modeling of the bacterial growth curve, Appl. Environ. Microbiol, pp.56-1875, 1990.

. Peck-radosavljevic, Five-year on-treatment efficacy of lamivudine-, tenofovir-and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients, J. Viral Hepat, vol.19, 2012.

G. V. Matthews, R. J. Ali, A. Avihingsanon, J. Amin, R. Hammond et al., Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals, PLoS ONE, vol.48, issue.4
DOI : 10.1371/journal.pone.0061297.t003

E. Lauret, M. L. González-diéguez, M. Rodríguez, M. González, S. Melón et al., Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance, Liver International, vol.56, issue.1, pp.140-147, 2015.
DOI : 10.1016/j.jhep.2011.09.024

S. Suzuki, Y. Saitoh, K. Arase, M. Ikeda, S. Kobayashi et al., Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients, J. Viral Hepat, vol.21, pp.802-808, 2014.

P. Marcellin, F. Zoulim, C. Hézode, X. Causse, B. Roche et al., Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France, Digestive Diseases and Sciences, vol.49, issue.Suppl, pp.10-10620, 1007.
DOI : 10.1002/hep.22885

Y. C. Chen, W. J. Jeng, R. N. Chien, C. M. Chu, and Y. F. Liaw, Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection, Alimentary Pharmacology & Therapeutics, vol.46, issue.12, pp.1311-1318, 2016.
DOI : 10.1159/000074999

C. Y. Maeng, C. J. Ryu, P. Gripon, C. Guguen-guillouzo, and H. J. Hong, Fine mapping of virusneutralizing epitopes on hepatitis B virus PreS1, Virology, pp.270-279, 2000.

A. U. Neumann, S. Phillips, I. Levine, S. Ijaz, H. Dahari et al., Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells, Hepatology, vol.11, issue.Pt. 2, pp.52-875, 2010.
DOI : 10.1038/nm1244

P. Marcellin, E. J. Gane, R. Flisiak, M. P. Manns, K. Kaita et al., Evidence for ongoing low-level viremia in patients with chronic hepatitis B receiving long-term nucleos(t)ide analog therapy, Hepatology, pp.60-1093, 2014.

J. Heinemann, G. Verheyen, M. Gerken, J. Roggendorf, and . Timm, Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable, J. Hepatol, vol.63, 2015.

K. H. Heermann, U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten et al., Large surface proteins of hepatitis B virus containing the pre-s sequence, J. Virol, pp.52-396, 1984.

T. I. Michalak, J. Y. Lau, B. M. Mcfarlane, G. J. Alexander, A. L. Eddleston et al., Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B, Clinical & Experimental Immunology, vol.55, issue.2, pp.227-232, 1995.
DOI : 10.3181/00379727-186-2-RC1

J. N. Wilson, D. J. Nokes, G. F. Medley, and D. Shouval, Mathematical model of the antibody response to hepatitis B vaccines: Implications for reduced schedules, Vaccine, vol.25, issue.18, 2007.
DOI : 10.1016/j.vaccine.2007.01.012

O. Launay, A. R. Rosenberg, D. Rey, N. Pouget, M. Michel et al., Trial Comparing 3 Strategies of Vaccination Against the Virus of Hepatitis B in HIV-Infected Patients) Group, Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial, JAMA Intern. Med, pp.176-603, 2016.

J. M. Ferrer-ríos, M. S. Sousa-martin, A. Mota, G. S. Gallego, and . Artacho, Response to vaccination against hepatitis B virus with a schedule of four 40-?g doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response, Transplant. Proc, vol.44, pp.1499-1501, 2012.

E. R. Nashan, J. Kuse, H. L. Klempnauer, M. P. Tillmann, and . Manns, HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration, J. Hepatol, vol.46, pp.635-644, 2007.

A. Floreani, V. Baldo, M. Cristofoletti, G. Renzulli, A. Valeri et al., Longterm persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers, Vaccine, pp.22-607, 2004.

P. Miailhes, M. Trabaud, P. Pradat, B. Lebouché, M. Chevallier et al., Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion, Clinical Infectious Diseases, vol.45, issue.5, pp.45-624, 2007.
DOI : 10.1086/520752

P. Michelone, F. Pugnale, V. Negro, M. U. Barnaba, and . Mondelli, Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections, J. Hepatol, vol.55, pp.53-60, 2011.

W. O. Böcher, E. Galun, H. Marcus, N. Daudi, D. Terkieltaub et al., Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of